Corey Hopkins

Collaboration seeks to develop new therapies for bone, other diseases

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

Growth factor blockade targets breast tumors

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.

Small molecule protects kidney filter

A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier.

Drug-like molecules aimed at improving treatment of Parkinson’s

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson’s treatments with fewer side effects.